Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Summary:
Ivermectin is an endectocide effective against endo- and ectoparasites and is widely used in mass drug administration (MDA) for neglected tropical diseases. It also kills malaria vectors that feed on treated individuals, making MDA with ivermectin a potential tool to reduce mosquito-driven malaria transmission. We conducted a cluster-randomized controlled trial in Kwale, Kenya (84 clusters; high bed net coverage >80%). Clusters were randomized 1:1 to receive ivermectin (400 μg/kg) or albendazole (400 mg, active control) once a month for three months during the “short rains.” Children aged 5–15 years were tested monthly for malaria infection for six months. Primary outcomes were malaria incidence and adverse events, analyzed using generalized estimating equations under the intention-to-treat principle. A total of 28,932 participants were enrolled. Ivermectin MDA reduced malaria incidence among children by 26% compared to control, with no safety concerns observed. We conclude that ivermectin MDA can reduce residual malaria transmission

Biography
Professor Marta Maia is an Associate Professor of the Nuffield Department of Medicine. She has a background in one health and epidemiology of vector-borne diseases. Prof Maia has over 15 years of experience working on the development and testing of malaria vector control interventions in East Africa, having worked on spatial repellents, topical repellents, attractive-targeted sugar baits, and endectocides. Most recently, she was the Principal investigator of the BOHEMIA trial in Kenya which aimed to evaluate mass drug administration (MDA) of ivermectin for reduction of malaria transmission. She is currently based in Kenya at the KEMRI Wellcome Trust Research Programme where she leads the Vector Unit.

Members of the university only.

OrganiserProfessor Angela Brueggemann (Oxford Population Health)
Organiser contact email addressalison.lewis@ndph.ox.ac.uk

Forthcoming events

Festival of Global Health – Spillover: Planet of Viruses

Wednesday, 26 November 2025, 4pm to 8pm @ Curzon Oxford, Westgate Shopping Centre, Oxford OX1 1NZ

Oliver Smithies Lecture

Thursday, 27 November 2025, 5.15am to 6.15am @ Gillis Lecture Theatre

Talk title: Agency and Preference: Attitudes Toward Vaccination and Epidemic Risks

Optimising global frameworks for pandemic relevant research

Monday, 01 December 2025, 1pm to 2pm @ BDI/OxPop Seminar Rooms

IDEU Symposium 2026

Wednesday, 04 March 2026 to Thursday, 05 March 2026 @ Richard Doll Building - Lecture Theatre